Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
Tiziana Masini(World Health Organization), Dennis Falzon(World Health Organization), Fuad Mirzayev(World Health Organization), Avinash Kanchar(World Health Organization), Askar Yedilbayev(World Health Organization Regional Office for Europe), Matteo Zignol(World Health Organization), Kerri Viney(World Health Organization)
Cited by 11
Related Papers
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
|The Lancet Infectious Diseases|2025|526
Global Incidence of Multidrug‐Resistant Tuberculosis
|The Journal of Infectious Diseases|2006|525
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe
|European Respiratory Journal|2019|130